• BIVDA members area

Members' Press Releases

From the monthly archives: September, 2013

We are pleased to present below all posts archived in 'September, 2013'. If you still can't find what you are looking for, try using the search box.

Results for the six months ended 30th June 2013 Highlights


  • Licenses/Sales/Services showed 50% growth
  • Largest contract to date with Thermo Fisher Scientific to develop advanced methods/assays to profile changes in key cancer pathways
  • After the EU ban in March, SensiDerm™ multiplex assay selected by Cosmetics Europe as an in vitro priority test for optimisation as a replacement for animal testing in cosmetics
  • TMT® reagents sales increased 25% - 50 abstracts from key opinion leaders at ASMS
  • Significant new tests launched in breast cancer and Amyloid Beta, Tau and Phosphotau in AD
  • SysQuant® coverage of phosphorylation sites increased from 2,200 to 11,000
  • Our PS110 and PS278-05 compounds against CK1d caused a dramatic drop in tau protein in AD

Read the rest of entry »

Oxford Immunotec Wins Place Again on The Sunday Times Hiscox Tech Track 100

Oxford, UK [Marlborough, MA]; 18th Sep 2013 – Oxford Immunotec has been awarded a place on the prestigious Sunday Times Tech Track 100 league table for the second year running. Ranking Britain's 100 private technology companies with the fastest-growing sales over the last three years, Tech Track 100 is compiled by Fast Track, the Oxford company that researches Britain’s top performing private companies.

Read the rest of entry »

Siemens to exhibit virtual product display for advanced diagnostic testing at IBMS

Siemens Healthcare Diagnostics will showcase its broad portfolio of diagnostic testing capabilities, from new assays and automation solutions to digital microscopy and online training at The Institute of Biomedical Science Congress 2013 (IBMS) in Birmingham. The Siemens solutions will be available to view on a virtual display and are designed to unite clinical and workflow excellence, assisting laboratories to run as effectively and efficiently as possible.

Read the rest of entry »